Experimental cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT06649227
Summary
This early-stage study is testing the safety of a personalized cell therapy called CD19 CAR-T for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The therapy involves collecting a patient's own immune cells, genetically modifying them to target cancer cells carrying the CD19 marker, and reinfusing them. The study will enroll 5 patients to monitor for side effects and see if the treatment shows any anti-leukemia activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ADULT AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Lille
RECRUITINGLille, 59000, France
Contact
Conditions
Explore the condition pages connected to this study.